Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenji Hashimoto

Showing results (41-50 of 861) with videos related to

Pageof 87
Sort By:
Current Psychiatry Reports|July 7, 2019
Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical FindingsKenji Hashimoto
Molecular Psychiatry|October 16, 2023
Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directionsKenji Hashimoto
Psychiatry Research|February 25, 2026
Sigma-1 receptor antagonism as a potential mechanism of sertraline-associated Alice in Wonderland syndromeKenji Hashimoto
Molecular Psychiatry|July 4, 2023
Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axisKenji Hashimoto
Expert Review of Neurotherapeutics|December 17, 2010
Role of the mTOR signaling pathway in the rapid antidepressant action of ketamineKenji Hashimoto
Current Pharmaceutical Design|March 2, 2011
Glycine transporter-1: a new potential therapeutic target for schizophreniaKenji Hashimoto
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|June 28, 2011
[Development of new therapeutic drugs based on the pathophysiology of schizophrenia]Kenji Hashimoto
Experimental Neurology|January 14, 2015
Targeting the sigma-1 receptor chaperone in the treatment of perinatal brain injuryKenji Hashimoto
Molecular Psychiatry|April 28, 2022
Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?Kenji Hashimoto
Central Nervous System Agents in Medicinal Chemistry|December 22, 2009
Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationshipKenji Hashimoto
Pageof 87

Showing results (41-50 of 861) with videos related to

Sort By:
Pageof 87
Current Psychiatry Reports|July 7, 2019
Recent Advances in the Early Intervention in Schizophrenia: Future Direction from Preclinical FindingsKenji Hashimoto
Molecular Psychiatry|October 16, 2023
Emerging role of the host microbiome in neuropsychiatric disorders: overview and future directionsKenji Hashimoto
Psychiatry Research|February 25, 2026
Sigma-1 receptor antagonism as a potential mechanism of sertraline-associated Alice in Wonderland syndromeKenji Hashimoto
Molecular Psychiatry|July 4, 2023
Detrimental effects of COVID-19 in the brain and therapeutic options for long COVID: The role of Epstein-Barr virus and the gut-brain axisKenji Hashimoto
Expert Review of Neurotherapeutics|December 17, 2010
Role of the mTOR signaling pathway in the rapid antidepressant action of ketamineKenji Hashimoto
Current Pharmaceutical Design|March 2, 2011
Glycine transporter-1: a new potential therapeutic target for schizophreniaKenji Hashimoto
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|June 28, 2011
[Development of new therapeutic drugs based on the pathophysiology of schizophrenia]Kenji Hashimoto
Experimental Neurology|January 14, 2015
Targeting the sigma-1 receptor chaperone in the treatment of perinatal brain injuryKenji Hashimoto
Molecular Psychiatry|April 28, 2022
Ketamine: anesthetic, psychotomimetic, antidepressant, or anthelmintic?Kenji Hashimoto
Central Nervous System Agents in Medicinal Chemistry|December 22, 2009
Sigma-1 receptors and selective serotonin reuptake inhibitors: clinical implications of their relationshipKenji Hashimoto
Pageof 87